Medius Holdings (3154) Fundamentals 2026 — P/E 13.7x, Revenue Analysis | SniperIQ
Medius Holdings (3154) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥17.6B, trading at ¥792.00 on the JPX. This SniperIQ fundamentals page covers Medius Holdings's valuation (P/E 13.7x, P/B 0.8x), profitability (net margin 0.4%), revenue (¥288.7B in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medius Holdings's market cap?
Medius Holdings (3154) has a market capitalization of approximately ¥17.6B, trading at ¥792.00 on the JPX. Market cap moves with the live share price.
What is Medius Holdings's P/E ratio?
Medius Holdings's trailing twelve-month P/E ratio is 13.7x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medius Holdings?
Medius Holdings runs a net profit margin of 0.4%, a gross margin of 11.5%, and an operating margin of 0.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medius Holdings generate?
Medius Holdings reported revenue of ¥288.7B for fiscal year 2024, with net income of ¥1.4B and earnings per share (EPS) of 61.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medius Holdings pay a dividend?
Medius Holdings offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Medius Holdings financially healthy?
Medius Holdings carries a debt-to-equity ratio of 1.14x and a current ratio of 1.09x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medius Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medius Holdings (3154) the key facts are: market cap ¥17.6B, P/E 13.7x, revenue ¥288.7B, 52-week range 773-890. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medius Holdings's full fundamentals live
Get Medius Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.